Express Pharma

JULY 6, 2025

The pharmaceutical industry is bracing for one of its most financially significant patent cliffs in over a decade, with multiple blockbuster drugs set to lose exclusivity by 2030. As a result, the US market is set to lose over $230 billion between 2025 and 2030.

Biosimilars 66

Biosimilars 66

Express Pharma

JANUARY 14, 2025

However, emerging biotech companies are poised to disrupt this landscape, with promising pipeline products expected to generate substantial revenue and challenge the market leaders by 2030, says GlobalData. billion) of 2030 sales. However, by 2030, GlobalData forecasts them to be ranked among the top 10 companies by GLP-1R sales.

Diabetes 105

Diabetes 105

Express Pharma

NOVEMBER 28, 2024

India’s pharmaceutical market, currently valued at approximately $60 billion, is projected to double by 2030. Getting this right will hold the key to winning a disproportionate market share in a large and expanding value pool (~$12B domestic market for global pharma companies by 2030).

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 105

Express Pharma

MARCH 25, 2025

billion in 2030. GlobalDatas report, Cell and Gene Therapies in Gastrointestinal Disorders Therapeutic Analysis, Treatment Options, Pricing and Reimbursement and Future Market, reveals that CGT market for GI disorders, as a standalone therapy area, is expected to increase from $47 million in 2023 to $187 million in 2030.

Compounding 66

Compounding 66

PharmExec

MAY 20, 2025

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses the company's nationwide push to reduce cardiovascular risk through free LDL-C testing, public-private partnerships, and implementation science initiativesall aimed at cutting CV events in half by 2030.

40

40

Express Pharma

NOVEMBER 5, 2024

The global enoxaparin market was valued at US $3,315 million in 2023 and is projected to reach US $5,415 million by 2030, growing at a rate of 7.1 per cent from 2024 to 2030. This achievement supports the company’s expansion in new markets and enhances its ability to meet the global demand for enoxaparin.

Pharmaceutical Manufacturing 105

Pharmaceutical Manufacturing 105

Express Pharma

JANUARY 14, 2025

The Indian nutraceutical market is set to grow sixfold by 2030 Kalka Prasad, AVP – Marketing, Crius Life, Crius Group The Indian nutraceutical market is projected to reach $64 billion by 2030. per cent from 2024 to 2030. per cent from 2023 to 2030. billion in 2023 and is expected to grow at a CAGR of 8.4

Diabetes 105

Diabetes Compounding 105

Drug Patent Watch

DECEMBER 10, 2024

from 2023 to 2030. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 billion in 2022 and is expected to grow at a compound annual growth rate of 5.3%

Drug Development 88

Drug Development Communication Pharmaceutical Companies Pharmaceutical Companies 88

Drug Patent Watch

DECEMBER 12, 2024

Generics 2030: Three strategies to curb the downward spiral. References Schulman, K. Options to Promote Competitive Generics Markets in the United States. JAMA, 314(14), 14691470. doi:10.1001/jama.2015.13498 2015.13498 KPMG. Retrieved from [link] The Commonwealth Fund. Strategies That Delay Market Entry of Generic Drugs.

Generic Medicine 84

Generic Medicine 84

Express Pharma

NOVEMBER 1, 2024

per cent through 2030, the industry faces significant challenges such as high production costs, waste, and energy-intensive processes. With the oligonucleotide and peptide therapeutics market projected to grow at an annual rate of 17.5

105

105

Fuld & Company Blog

NOVEMBER 11, 2024

The company has partnered with Energy Northwest to deploy four X-energy reactors generating 320 MW by the early 2030s, made an equity investment in X-energy as part of a $500 million fundraising round, and signed an MOU with Dominion Energy to explore SMR development in Virginia 1.

52

52

Express Pharma

FEBRUARY 12, 2025

billion by 2030, according to a GlobeNewsWire report. The nutraceutical market is expanding rapidly, valued at $6.11 billion in 2024 and projected to reach $11.55 However, pharma companies eager to tap into this growth, face a complex road ahead. Regulatory ambiguity, for instance, serves as a double-edged sword.

Documentation 99

Documentation Labelling 99

European Pharmaceutical Review

JULY 4, 2025

Only a few big pharma companies are positioned to grow revenue sustainably through 2030, stated GlobalData. As such, the US market is expected to lose over $230 billion over the next five years. Which blockbuster drugs could be impacted in the next pharmaceutical patent cliff?

Generic Medicine 52

Generic Medicine Biosimilars 52

Express Pharma

DECEMBER 20, 2024

billion square feet of healthcare space by 2030 and 2.9 This year alone, we witnessed the demand for healthcare infrastructure skyrocket, with estimates indicating a need for an additional 1.3 million hospital beds to meet global standards.

Hospitals 52

Hospitals 52

pharmacy mentor

JUNE 16, 2025

between 2023 and 2030, according to GrandView Research. While exact figures for the UK vary, analysts agree on a robust growth trajectory through 2030, driven by rising adoption of digital prescriptions, increased demand for convenience, and the expansion of private pharmacy services across the country. billion by 2032.

Online Pharmacies 52

Online Pharmacies Customer Service People Management Packaging 52

Express Pharma

JANUARY 17, 2025

As part of this, we have committed to reducing absolute Scope 1 and 2 GHG emissions by 42 per cent by the end of 2030 (2021 base year) and to set a supplier engagement target for Scope 3 emissions. The post Strengthening our presence within APAC through increased penetration is a key focus appeared first on Express Pharma.

Labelling 104

Labelling Packaging 104

Pharmaceutical Business Review

JULY 4, 2025

In June this year, Hikma Pharmaceuticals USA announced an investment of $1bn by 2030 to further expand its US manufacturing and R&D capabilities. Its compatibility with automated dispensing cabinets further integrates it into existing hospital workflows.

Hospitals 52

Hospitals Compounding 52

Express Pharma

DECEMBER 17, 2024

The sector is targeting a remarkable $130 billion by 2030 and a visionary $450 billion by 2047. India’s pharmaceutical industry, a global leader in generics, is poised for exponential growth.

Biosimilars 104

Biosimilars 104

STAT

FEBRUARY 7, 2025

The goal, first announced in November 2023, is to improve longevity and reduce disparities caused by heart- and diabetes-related diseases by 5% by 2030 and deaths due to screenable cancers by 20% by 2030.    Read the rest…

Diabetes 166

Diabetes 166

Express Pharma

NOVEMBER 13, 2024

India’s pharma industry is on an impressive growth trajectory, expected to reach $65 billion by 2024 and to double to $130 billion by 2030. Renowned as a comprehensive, one-stop destination for innovative, cost-effective solutions, the expo will be showcasing the pharmaceutical industry’s modernisation, innovation, and sustainability.

Biosimilars 105

Biosimilars Pharmaceutical Manufacturing Hospitals 105

Express Pharma

JANUARY 16, 2025

Aligned with the ‘Atmanirbhar Bharat’ vision, the sector seeks targeted initiatives to achieve its $130 billion goal by 2030. A key demand is the reintroduction of a 200 per cent tax deduction for R&D spending, particularly for novel drugs.

105

105

Beckers Hospital Review

JULY 16, 2025

Providence aims to become the best place to give and receive care by 2030, backed by a technology-enabled transformation strategy. Tracking progress and defining success Providence is finalizing short-term goals for 2027 as it tracks progress toward its 2030 vision. President and CEO Erik Wexler detailed the Renton, Wash.-based

Documentation 59

Documentation Hospitals 59

Drug Patent Watch

DECEMBER 11, 2024

Future Directions and Strategies By 2030, generics manufacturers will need to shift from the status quo and explore new avenues for change. Generics 2030: Three Strategies to Curb the Downward Spiral. This includes developing higher-value generics, investing in innovation, and creating differentiated products.

Drug Development 96

Drug Development 96

Express Pharma

JULY 15, 2025

24 mega-selling drugs with combined annual sales exceeding $250 billion will lose patent protection by 2030 and will soon be open for generic manufacturing.

Hospitals 93

Hospitals 93

Express Pharma

MARCH 20, 2025

GlobalDatas report, Endometriosis Market Size and Trend Report, reveals that the endometriosis market size across the seven major markets* (7MM) is expected to achieve a compound annual growth rate of more than 9 per cent during 2020-2030.

Dosage 66

Dosage Compounding Hospitals 66

Pharmacy Times

JUNE 18, 2025

The Healthy People 2030 initiative addresses structural health care inequalities and implements programs to ameliorate SDOH. Healthy People 2030. Each unique set of economic, educational, social, and environmental circumstances significantly affects their quality of life and health. REFERENCES 1. Social determinants of health.

Pharmacy Technician 26

Pharmacy Technician Immunity Immunization Diabetes 26

Pharmacy Times

JUNE 9, 2025

2019;380:2020-2030. Global Initiative for Asthma. Accessed June 9, 2025. Beasley R, Holliday M, Reddell HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med.

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Hospitals Pharmacy Management 29

European Pharmaceutical Review

APRIL 10, 2025

In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. The PFAS regulatory challenge As a result, in the EU, a joint PFAS Restriction Proposal under REACH was submitted in 2023, aiming for a full ban on all PFAS by 2028/2030. There is worldwide concern around the use of PFAS.

Pharmaceutical Manufacturing 59

Pharmaceutical Manufacturing Packaging Documentation Communication 59

Express Pharma

JANUARY 28, 2025

Both private biotech companies and the government have emerged as key enablers, propelling the sector towards achieving a transformative $300 billion bioeconomy milestone by 2030.

100

100

PharmaVoice

JUNE 27, 2025

Now, the WHO’s aggressive goal to “ end HIV/AIDS ” by 2030 could be hampered by dramatic reductions in U.S. million Americans are infected with HIV, but the disease disproportionately impacts people in sub-Saharan Africa. Daiichi Sankyo’s ADC programs also include candidates it’s developing with Merck & Co.

Vaccines 130

Vaccines Dosage Packaging Immunity 130

Express Pharma

DECEMBER 11, 2024

billion in 2030, with the pediatric and adult segments accounting for $2.2 Six more products in late-stage development have potential to launch by 2030. Edits made by EP News Bureau The post Respiratory syncytial virus prophylactic market to surpass $6 bn across 8MM in 2030 appeared first on Express Pharma. billion and $4.0

Vaccines 102

Vaccines Compounding 102

Express Pharma

JANUARY 17, 2025

We have committed to reduce our scope 1 and 2 GHG emissions by 42 per cent (absolute) by the end of 2030 (from a 2021 basis). As a first step toward this ambition, Lonza has set Near-Term GHG emissions reduction targets that have been validated by the Science-Based Targets initiative (SBTi).

Dosage 104

Dosage Pharmaceutical Manufacturing Packaging Drug Development 104

Big Molecule Watch

APRIL 30, 2025

According to the press release, this is the third biosimilar from the CuraTeQ portfolio to receive a positive opinion from CHMP in the last five months and the company aims to launch at least 10 biosimilars across oncology and immunology therapy by 2030.

Biosimilars 52

Biosimilars 52

Express Pharma

FEBRUARY 17, 2025

” Projected impact on productivity The EY study estimates that by 2030, GenAI could improve productivity in pharmaceutical and healthcare industries by 30 per cent to 40 per cent. The research, which analysed more than 450 roles, highlights specific areas of transformation.

Documentation 71

Documentation Customer Service Pharmaceutical Companies Pharmaceutical Companies 71

European Pharmaceutical Review

APRIL 2, 2025

Therefore, to deliver a biosimilar pipeline by 2030, new questions need to be addressed across the biosimilar life cycle [and]coordinated action at both EU and national levels is required to support the future biosimilar landscape. Feedback on the reflection paper is open until 30 September 2025.

Biosimilars 52

Biosimilars 52

Pharmacy Times

JUNE 19, 2025

With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. 2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025.

Pharmacy Technician 26

Pharmacy Technician Diabetes Compounding Compounding Pharmacies 26

Pharmacy Times

JUNE 19, 2025

million deaths in 2019, and this is predicted to increase to approximately 23 million annual deaths by 2030. A steady increase in CVD-related deaths resulted in approximately 18.6 1 CVDs are disorders affecting the heart and blood vessels.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Hospitals Diabetes 26